Organizational Impact of Immunotherapies in Advanced Cancers in France

Author:

Grumberg Valentine12ORCID,Chouaïd Christos34ORCID,Gaudin Anne-Françoise1ORCID,Le Tourneau Christophe56,Marabelle Aurélien7ORCID,Bongiovanni-Delarozière Isabelle8,Cotté François-Emery1,Borget Isabelle29ORCID

Affiliation:

1. Bristol Myers Squibb France, Rueil-Malmaison, France

2. Oncostat, U1018, CESP, Inserm, Paris-Saclay University, “Ligue Contre le Cancer” Labeled Team, Villejuif, France

3. Department of Chest Medicine, Créteil University Hospital, Créteil, France

4. INSERM U955, UPEC, IMRB, Créteil, France

5. Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France

6. INSERM U900 Research Unit, Paris-Saclay University, Saint-Cloud, France

7. Drug Development Department (DITEP), INSERM U1015, Université Paris Saclay, Gustave Roussy, Villejuif, France

8. Real-World Solutions, IQVIA France, Paris, France

9. Department of Biostatistics and Epidemiology, Gustave Roussy, Paris-Saclay University, Villejuif, France

Abstract

PURPOSE In 2020, the French National Authority for Health ( Haute Autorité de Santé) published a methodologic guide called organizational impact (OI) cartography to define and structure assessment of the OI of health technologies. As immunotherapies are associated with extended survival and improved quality of life in advanced cancer, we aimed to identify OIs that immunotherapies had on health care systems and professionals. To our knowledge, we suggest the first implementation for OI assessment on the basis of the cartography. METHODS A literature review was conducted, and interviews with health care professionals (HCPs) were performed to identify OIs of immunotherapies. They were asked if immunotherapies had OIs classified into three macrocriteria, namely, impact on the care process (six criteria), impact on capacities and skills required (six criteria), and impact on society (four criteria). If an OI was mentioned for a criterion, information on its impact (minor/moderate/major) and its timing was collected. We considered that an OI existed when 75% of HCPs mentioned an impact for a given criterion. RESULTS Overall, 27 HCPs were interviewed. For 12 of 16 criteria, most HCPs mentioned an impact, whereas the literature identified impacts for 11 criteria. Four criteria (skills and transfer between HCPs, scheduling capabilities, and social relationship) had consensus among HCPs and a high impact; two criteria (rhythm or care duration, working/living conditions) showed consensus but a moderate impact; two criteria (funding and scheduling capabilities cross-structure) had a high impact but no consensus. For eight criteria (as environment or inequity), there was no consensus and moderate impact. CONCLUSION The introduction of immunotherapies for advanced cancer has had an important OI in France, regarding capacities and skills. Further research using qualitative analysis of interviews will provide more information regarding OI.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3